Short-Acting B2 Agonists Market Growth Through 2030 Creates New Strategic Opportunities
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Short-Acting B2 Agonists Market Forecast: What Market Value Is Expected By 2030?
The market for short-acting beta-2 agonists has experienced consistent expansion over the past few years. Projections indicate an increase from $4.4 billion in 2025 to $4.58 billion in 2026, representing a compound annual growth rate (CAGR) of 4.1%. This historical growth was driven by several factors, including a high incidence of asthma, urgent requirements for respiratory care, a strong demand for quick-acting bronchodilators, established treatment guidelines in hospital settings, and the widespread accessibility of generic medications.
The short-acting beta-2 agonists market is projected to maintain a steady upward trajectory over the coming years, reaching an estimated $5.39 billion by 2030 with a compound annual growth rate (CAGR) of 4.2%. This anticipated expansion during the forecast period is driven by factors such as rising air pollution levels, an increasing burden of respiratory diseases in urban areas, greater reliance on home-use inhalers, growing numbers of pediatric asthma patients, and the broadening scope of outpatient respiratory care services. Key developments shaping this period include the ongoing reliance on these agents as a first-line rescue treatment, higher incidence rates of asthma and chronic obstructive pulmonary disease (COPD), a growing preference for inhalation-based delivery methods, an expansion in home-based respiratory care, and the increasing availability of generic short-acting beta-2 agonist products.
Download A Free Sample Report For Comprehensive Market Insights:
Short-Acting B2 Agonists Market Development Factors: Which Trends Are Supporting Demand?
The rising frequency of chronic obstructive pulmonary disease (COPD) is anticipated to drive forward the expansion of the short-acting B2 agonists market. COPD is a persistent lung condition characterized by breathing challenges and diminished airflow, often resulting from extended contact with toxic gases or cigarette smoke. This increase in COPD prevalence is linked to heightened exposure to air pollution, where prolonged intake of contaminants such as particulate matter and harmful gases can damage lung tissue and speed up the disease’s progression. Short-acting β2-agonists (SABAs) are employed in COPD management to provide rapid relief from symptoms like breathlessness by relaxing the muscles in the airways. They function as rescue therapies during exacerbations but are not intended for ongoing control. For example, in December 2023, a research study featured in JAMA Network Open, a medical journal published by the American Medical Association, estimated that global COPD cases might approach 600 million by 2050, representing a 23% rise in prevalence. Consequently, the growing occurrence of chronic obstructive pulmonary disease is set to boost the short-acting B2 agonists market.
Short-Acting B2 Agonists Market Segmentation And Category Breakdown
The short-acting b2 agonists market covered in this report is segmented –
1) By Type: Albuterol, Levalbuterol, Metaproterenol, Other Types
2) By Indication: Asthama, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm
3) By Administration Route: Inhalation, Oral, Injection
4) By End User: Hospitals, Clinics, Home Healthcare Settings
Subsegments:
1) By Albuterol: Inhalers, Nebulizers, Tablets, Syrups
2) By Levalbuterol: Inhalers, Nebulizers, Oral Solutions
3) By Metaproterenol: Inhalers, Syrups
4) By Other Types: Terbutaline, Pirbuterol, Salbutamol
Short-Acting B2 Agonists Market Transformation Trends: Which Innovations Are Driving Change?
Leading firms in the short-acting B2 agonists sector are prioritizing the development of advanced technological solutions, like pressurized metered-dose inhalers (pMDI), to effectively address acute symptom management. The pressurized metered-dose inhaler (pMDI) is a compact device that utilizes a propellant-driven spray to administer a precise medication dose directly to the lungs in aerosol form. It is frequently employed for handling respiratory illnesses such as asthma and COPD. In January 2023, for example, AstraZeneca, a UK-based pharmaceutical and biotech firm, secured US Food and Drug Administration (FDA) clearance for Airsupra (albuterol/budesonide). This product is a pioneering pressurized metered-dose inhaler (pMDI) that blends two active agents into a fixed-dose formulation. The combination includes albuterol, a short-acting beta2-agonist (SABA) for immediate bronchodilation, and budesonide, an inhaled corticosteroid (ICS) aimed at decreasing inflammation. Within the US, this unique mixture has been authorized for on-demand use in both treating and preventing bronchoconstriction among adults with asthma. Moreover, it also lessens the likelihood of exacerbations, offering a well-rounded strategy for asthma care.
Short-Acting B2 Agonists Market Competitive Analysis Of Major Industry Participants
Major companies operating in the short-acting b2 agonists market are AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Apotex Inc., Perrigo Company plc, Aurobindo Pharma Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Orion Corporation, Beximco Pharmaceuticals Ltd., Micro Labs Limited, Neuland Laboratories Limited, Vectura Group plc, Nephron Pharmaceuticals Corporation, AdvaCare Pharma USA LLC, Midas Care Pharmaceuticals Pvt Ltd.
Access The Complete Short-Acting B2 Agonists Market Report:
Short-Acting B2 Agonists Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the short-acting B2 agonists market in 2025. The regions covered in the short-acting b2 agonists market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
